“Onvansertib + Abiraterone- Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the ONVANSERTIB + ABIRATERONE in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Onvansertib, a third-generation first-in-class, adenosine triphosphate inhibitor is showing promise when combined with chemotherapies and targeted agents. The combination of onvansertib (PCM-075) with abiraterone acetate (Zytiga) decreased the prostate-specific antigen (PSA) levels in most of the evaluable patients treated in a phase II study (NCT03414034), which used the combination in adult patients with metastatic castration-resistance prostate cancer (mCRPC), according to a press release from onvansertib developer, Trovagene, Inc. The results presented at the European Multidisciplinary Congress on Urological Cancers (EMUC) show that after 3 months of treatment with onvansertib plus abiraterone acetate, 60% of patients has a partial response (PR) or stable disease.
Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ONVANSERTIB + ABIRATERONE.
• The report contains forecasted sales for ONVANSERTIB + ABIRATERONE till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Prostate cancer.
• The report also features the SWOT analysis with analyst insights and key findings of ONVANSERTIB + ABIRATERONE.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ONVANSERTIB + ABIRATERONE Analytical Perspective by DelveInsight
• In-depth ONVANSERTIB + ABIRATERONE Market Assessment
This report provides a detailed market assessment of ONVANSERTIB + ABIRATERONE in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
• ONVANSERTIB + ABIRATERONE Clinical Assessment
The report provides the clinical trials information of ONVANSERTIB + ABIRATERONE covering trial interventions, trial conditions, trial status, start and completion dates.
• In the coming years, the market scenario for Prostate cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence ONVANSERTIB + ABIRATERONE dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Prostate cancer are giving market competition to ONVANSERTIB + ABIRATERONE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of ONVANSERTIB + ABIRATERONE.
• Our in-depth analysis of the forecasted sales data of ONVANSERTIB + ABIRATERONE from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ONVANSERTIB + ABIRATERONE.
• Which company is developing ONVANSERTIB + ABIRATERONE along with the phase of the clinical study?
• What is the technology utilized in the development of ONVANSERTIB + ABIRATERONE?
• What is the product type, route of administration and mechanism of action of ONVANSERTIB + ABIRATERONE?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ONVANSERTIB + ABIRATERONE development?
• What are the key designations that have been granted to ONVANSERTIB + ABIRATERONE?
• What is the forecasted market scenario of ONVANSERTIB + ABIRATERONE?
• What is the history of ONVANSERTIB + ABIRATERONE and what is its future?
• What is the forecasted sales of ONVANSERTIB + ABIRATERONE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to ONVANSERTIB + ABIRATERONE?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook